AstraZeneca, SWIBCo Launch Stem Cell Cardiovascular Therapy Collaboration – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
AstraZeneca, SWIBCo Launch Stem Cell Cardiovascular Therapy Collaboration
Genetic Engineering & Biotechnology News AstraZeneca will develop novel cardiovascular and catheter-based therapies using Procella Therapeutics’ stem cell technology and Smartwise’s catheter injection method, it was disclosed today, through a collaboration that could generate up to $320 … |
Endpoints News |
Is biopharma’s first $1.5M therapy now in Phase III?
Endpoints News Keying off of Spark Therapeutics’ rollout of Luxturna as the first approved gene therapy in the US, the analysts at Leerink have been crunching the numbers on what the first hemophilia gene therapies could fetch. And by raising their estimate to $1.5 … |
Endpoints News |
Is biopharma’s first $1.5M therapy now in Phase III?
Endpoints News Keying off of Spark Therapeutics’ rollout of Luxturna as the first approved gene therapy in the US, the analysts at Leerink have been crunching the numbers on what the first hemophilia gene therapies could fetch. And by raising their estimate to $1.5 … |